Table 1.
Cancer Cases* | Noncancer Controls* | |||
---|---|---|---|---|
n | % | n | % | |
Sample size | 3,512 | 7,024 | ||
Age groupings | ||||
21–35 | 235 | 6.7 | 470 | 6.7 |
36–50 | 1,199 | 34.1 | 2,398 | 34.1 |
51–64 | 2,078 | 59.2 | 4,156 | 59.2 |
Females | 1,615 | 46.0 | 3,230 | 46.0 |
Race groupings | ||||
White | 1,529 | 43.5 | 3,058 | 43.5 |
Black | 1,608 | 45.8 | 3,216 | 45.8 |
Other | 375 | 10.7 | 750 | 10.7 |
Stage groupings | ||||
Local | 454 | 12.9 | ||
Regional | 974 | 27.7 | ||
Distant | 1,654 | 47.1 | ||
Unknown | 430 | 12.2 | ||
Cancer site | ||||
Lung | 1,135 | 32.3 | ||
Digestive organs | 816 | 23.2 | ||
Oropharynx | 257 | 7.3 | ||
Female breast | 222 | 6.3 | ||
Female genital organs | 212 | 6.0 | ||
Urinary tract | 114 | 3.3 | ||
Other cancers | 755 | 21.5 | ||
Time to death from cancer diagnosis | ||||
Within 3 months | 825 | 23.5 | ||
3–6 months | 734 | 20.9 | ||
7–12 months | 982 | 28.0 | ||
More than 12 months | 971 | 27.6 | ||
Unadjusted 4-month cost ($)† | $34,749 | $24,109 |
Sample includes all cancer and noncancer patients with 4 months of continuous enrollment before death.
Unadjusted cost for the 4-month period before death in 2003 dollars.